In this review:
Duration of oxaliplatin chemotherapy for stage III colon cancer
CAPOX continuous vs intermittent oxaliplatin for stage II/III colon cancer
Oxaliplatin chemotherapy duration for high-risk stage II colon cancer
Recurrence-free survival managed by watch and wait in rectal cancer
Vemurafenib for BRAF-mutant colorectal cancer
Encorafenib + cetuximab for BRAF-mutant colorectal cancer
Cost-effectiveness of encorafenib + cetuximab
Short-course radiotherapy + chemotherapy before total mesorectal excision
Biweekly cetuximab + FOLFOX6 first-line in RAS wild-type mCRC
Cetuximab every-2-weeks vs weekly for RAS wild-type metastatic colorectal cancer
Please login below to download this issue (PDF)